Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

About The Study: In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 ...

I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS grew in the double-digit percentages. Roche had 16 “blockbuster ...

"It is estimated that by 2030, 30 million GLP-1 [receptor agonist] prescriptions will have been dispensed in the U.S. Despite the rarity of NAION, the large number of users of these drugs can ...